Structured reviews will accelerate ANDAs
Executive Summary
Testing and implementing a more structured, computer-aided assessment process for abbreviated new drug applications (ANDAs) will enable the US Food and Drug Administration (FDA) to accelerate approvals on their first review cycle, according to Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER).
You may also be interested in...
NDAs, BLAs To Start Getting KASA Quality Risk Assessments After Successful Pilot With ANDAs
Internal review system reduces US FDA’s administrative work for OPQ risk assessments; agency’s standards will not change, and sponsors will not need to modify applications. Advisory committee endorses expansion, which will roll out to different application types over several years.
Pressure Mounts For German Tender Reforms
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
Teva Leapfrogs Mylan And Sandoz On Linaclotide
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.